14 results on '"Ineffective Hematopoiesis"'
Search Results
2. A multicenter report on the natural history of myelodysplastic syndromes in very old patients (aged over 85 years)
- Author
-
Desmond O'Neill, Philip Murphy, Clodagh Keohane, Patrick Hogan, Su Wai Maung, Melanie Strickland, Ronan Desmond, Daniel H. Ryan, Elizabeth O'Connell, Mohammad Khan, Peter McCarthy, John Quinn, Vitaliy Mykytiv, Mary R. Cahill, John McHugh, Laura S McDonald, Eileen Kelleher, and Helen Enright
- Subjects
Male ,Cancer Research ,Pediatrics ,medicine.medical_specialty ,Treatment outcome ,Mild cytopenia ,03 medical and health sciences ,Disease susceptibility ,0302 clinical medicine ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Aged, 80 and over ,Ineffective Hematopoiesis ,Old patients ,business.industry ,Myelodysplastic syndromes ,Disease Management ,Myeloid leukemia ,Hematology ,Prognosis ,medicine.disease ,Natural history ,Treatment Outcome ,Oncology ,Myelodysplastic Syndromes ,030220 oncology & carcinogenesis ,Female ,Disease Susceptibility ,business ,030215 immunology - Abstract
Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and risk of evolution to acute myeloid leukemia (AML) [1]. Presentation varies from mild cytopenia to profound symptom...
- Published
- 2019
3. BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes
- Author
-
Sudipto Mukherjee, Bartlomiej P Przychodzen, Jaroslaw P. Maciejewski, Aziz Nazha, Cassandra M. Hirsch, Hassan Awada, Nour Abuhadra, Karam Al-Issa, Mikkael A. Sekeres, Anjali S. Advani, Ahed Makhoul, and Vera Adema
- Subjects
Ineffective Hematopoiesis ,Cancer Research ,Heterogeneous group ,Myelodysplastic syndromes ,Clonal architecture ,Hematology ,Biology ,medicine.disease ,Somatic evolution in cancer ,Article ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,hemic and lymphatic diseases ,030220 oncology & carcinogenesis ,Mutation (genetic algorithm) ,DNA Mutational Analysis ,Cancer research ,medicine ,sense organs ,skin and connective tissue diseases ,030215 immunology - Abstract
To the Editor,The myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic conditions characterized by dysplastic changes and ineffective hematopoiesis [1]. Almost all patients with...
- Published
- 2019
4. Coincidence of 5q deletion and the JAK2V617F mutation: report of two patients with overlapping myelodysplastic and myeloproliferative features and review of the literature
- Author
-
Evgenii Shumilov, Ulrike Bacher, Nicolas Bonadies, Yara Banz, Susanne Bürki, Johanna Flach, Myriam Legros, Elisabeth Oppliger-Leibundgut, Alicia Rovó, Martin Fiedler, and Anne Angelillo-Scherrer
- Subjects
Ineffective Hematopoiesis ,Cancer Research ,Mutation ,business.industry ,Myelodysplastic syndromes ,Hematology ,medicine.disease ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,Myelodysplastic–myeloproliferative diseases ,Dysplasia ,hemic and lymphatic diseases ,030220 oncology & carcinogenesis ,medicine ,Cancer research ,Missense mutation ,Stem cell ,business ,030215 immunology ,Comparative genomic hybridization - Abstract
Myelodysplastic syndromes (MDS) represent a wide range of malignant hematological stem cell disorders characterized by ineffective hematopoiesis with dysplasia, peripheral cytopenias, and a propens...
- Published
- 2018
5. Prognostic mutations in persons with isolated neutropenia myelodysplastic syndrome
- Author
-
Zefeng Xu, Zhongxun Shi, Liwei Fang, Gang Huang, Hongli Zhang, Lijuan Pan, Bing Li, Naibo Hu, Robert Peter Gale, Zhijian Xiao, Huijun Huang, Shiqiang Qu, and Tiejun Qin
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Neutropenia ,Adolescent ,Article ,Myeloid Neoplasm ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,hemic and lymphatic diseases ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Young adult ,Survival rate ,Aged ,Aged, 80 and over ,Ineffective Hematopoiesis ,business.industry ,Myeloid leukemia ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,Combined Modality Therapy ,Survival Rate ,Increased risk ,Dysplasia ,Myelodysplastic Syndromes ,030220 oncology & carcinogenesis ,Mutation ,Female ,business ,Follow-Up Studies ,030215 immunology - Abstract
Myelodysplastic syndrome (MDS) is a heterogeneous clonal myeloid neoplasm of ineffective hematopoiesis, dysplasia and an increased risk of progression to acute myeloid leukemia (AML) [1]. Although ...
- Published
- 2019
6. A novel t(3;9)(q21.2; p24.3) associated with SMARCA2 and ZNF148 genes rearrangement in myelodysplastic syndrome
- Author
-
Angela Minervini, Luisa Anelli, Ciro Leonardo Pierri, Cosimo Cumbo, Paola Casieri, Giuseppina Tota, Luciana Impera, Crescenzio Francesco Minervini, Paola Carluccio, Alessandra Ricco, Francesco Albano, Claudia Brunetti, Nicoletta Coccaro, Antonella Zagaria, Paola Orsini, and Giorgina Specchia
- Subjects
0301 basic medicine ,Ineffective Hematopoiesis ,Cancer Research ,medicine.medical_specialty ,Myeloid ,Hematology ,business.industry ,Myelodysplastic syndromes ,Myeloid leukemia ,Chromosomal translocation ,Karyotype ,medicine.disease ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,medicine.anatomical_structure ,Oncology ,hemic and lymphatic diseases ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Cancer research ,business ,Gene - Abstract
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal myeloid disorders characterized by ineffective hematopoiesis and an increased risk of transformation to acute myeloid leukemia (A...
- Published
- 2017
7. Copper deficiency mimicking myelodysplastic syndrome
- Author
-
David Westerman, Paul Turner, John F. Seymour, Piers Blombery, and Kirsty Rady
- Subjects
Ineffective Hematopoiesis ,Cancer Research ,medicine.medical_specialty ,Hematology ,Anemia ,business.industry ,Myelodysplastic syndromes ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Oncology ,hemic and lymphatic diseases ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Cancer research ,Bone marrow ,Differential diagnosis ,Stem cell ,Copper deficiency ,business ,030215 immunology - Abstract
Myelodysplastic syndromes (MDS) are a group of clonal marrow stem cell disorders characterized by progressive peripheral cytopenias and ineffective hematopoiesis with an associated risk of progress...
- Published
- 2015
8. Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis
- Author
-
Monica Usai, Antonio Maccioni, Giorgio La Nasa, Michela Piga, Alessandra Perra, Giovanni Caocci, Roberto Mascia, and Francesca Murgia
- Subjects
Cancer Research ,Ruxolitinib ,medicine.medical_specialty ,Bone marrow fibrosis ,03 medical and health sciences ,0302 clinical medicine ,Bone Marrow ,Internal medicine ,Nitriles ,Humans ,Medicine ,Myelofibrosis ,Protein Kinase Inhibitors ,Janus Kinases ,Ineffective Hematopoiesis ,Hematology ,business.industry ,medicine.disease ,Extramedullary hematopoiesis ,Pyrimidines ,Treatment Outcome ,medicine.anatomical_structure ,Cellular Microenvironment ,Oncology ,Primary Myelofibrosis ,030220 oncology & carcinogenesis ,Mutation ,Immunology ,Cancer research ,Pyrazoles ,Bone marrow ,business ,Janus kinase ,030215 immunology ,medicine.drug - Abstract
Myelofibrosis (MF) is characterized by progressive bone marrow fibrosis, ineffective hematopoiesis and extramedullary hematopoiesis with splenomegaly. The primary symptoms resulting from peripheral...
- Published
- 2015
9. Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia
- Author
-
Kristina Battista, Karen W.L. Yee, Rena Buckstein, John M. Storring, Michael J. Kovacs, Anargyros Xenocostas, Richard A. Wells, Andre C. Schuh, S. Percy Ivy, Eunice S. Wang, Amit M. Oza, Kang Howson-Jan, and Lisa Wang
- Subjects
Oncology ,Ineffective Hematopoiesis ,Cancer Research ,medicine.medical_specialty ,Sunitinib ,business.industry ,Myelodysplastic syndromes ,Chronic myelomonocytic leukemia ,Myeloid leukemia ,Hematology ,Sunitinib malate ,medicine.disease ,Clinical trial ,Leukemia ,hemic and lymphatic diseases ,Internal medicine ,medicine ,business ,medicine.drug - Abstract
Myelodysplastic syndromes (MDS) are a heterogeneous group of malignant clonal disorders characterized by ineffective hematopoiesis and risk of progression to acute myeloid leukemia (AML) [1]. Recep...
- Published
- 2014
10. DNA micro-array analysis of myelodysplastic syndrome
- Author
-
Hiroyuki Mano
- Subjects
Ineffective Hematopoiesis ,Cancer Research ,Gene Expression Profiling ,CD34 ,Myeloid leukemia ,Hematology ,Biology ,medicine.disease ,Sensitivity and Specificity ,Gene expression profiling ,Leukemia ,Haematopoiesis ,Oncology ,Leukemia, Myeloid ,Myelodysplastic Syndromes ,hemic and lymphatic diseases ,Acute Disease ,Immunology ,Cancer research ,medicine ,Humans ,Progenitor cell ,Gene ,Oligonucleotide Array Sequence Analysis - Abstract
Myelodysplastic syndrome (MDS) is an enigmatic disorder characterized by ineffective hematopoiesis and dysplastic morphology of blood cells. The clinical course of MDS consists of distinct stages, with early stages often progressing to advanced ones or to acute myeloid leukemia (AML). Little is known of the molecular pathogenesis of MDS or of the mechanism of its stage progression. DNA micro-array analysis, which allows simultaneous monitoring of the expression levels of tens of thousands of genes, has the potential to provide insight into the pathophysiology of MDS. Several studies have applied this new technology to compare gene expression profiles either between MDS and the healthy condition, among the different stages of MDS or between MDS-derived AML and de novo AML. Selection of an appropriate hematopoietic fraction is important for such studies, which to date have been performed with differentiated granulocytes, CD34+ progenitors and CD133+ immature cells. These studies have revealed that each stage of MDS has its own 'molecular signature', indicating the feasibility of differential diagnosis of MDS based on gene expression profile. They have also demonstrated that the current clinical diagnosis of MDS results in the misclassification of patients with regard to these molecular signatures.
- Published
- 2006
11. Serum Levels of CD137 Ligand and CD178 are Prognostic Factors for Progression of Myelodysplastic Syndrome
- Author
-
Claudio Denzlinger, Helga Schmetzer, Gary C. Starling, Helmut R. Salih, Peter A. Kiener, and Volkmar Nuessler
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Fas Ligand Protein ,Time Factors ,Receptors, Nerve Growth Factor ,Disease ,Biology ,Ligands ,Receptors, Tumor Necrosis Factor ,Fas ligand ,Pathogenesis ,Tumor Necrosis Factor Receptor Superfamily, Member 9 ,Antigens, CD ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Aged ,Aged, 80 and over ,Ineffective Hematopoiesis ,Cytopenia ,Membrane Glycoproteins ,Hematology ,Middle Aged ,Prognosis ,Ligand (biochemistry) ,medicine.disease ,medicine.anatomical_structure ,Apoptosis ,Myelodysplastic Syndromes ,Disease Progression ,Cancer research ,Female ,Bone marrow - Abstract
Excess apoptosis leading to ineffective hematopoiesis is a common feature of myelodysplastic syndrome (MDS). CD178 (Fas ligand/APO-1 ligand) and CD137 ligand (CD137L), 2 molecules involved in the regulation of apoptosis, have previously been found in sera of patients with malignancies and have been hypothesized to participate in the pathogenesis of various diseases. We analyzed sera of patients with MDS and found that while time to progression of MDS correlated with the IPSS score there was no correlation of CD137L or CD178 serum levels with this score or with karyotype, bone marrow blast count or cytopenia. However, when cut-off-values for significant differentiation between cases with higher/lower levels of these molecules were determined we found that high levels of soluble CD137L (sCD137L) and low serum levels of soluble CD178 (sCD178) correlate with statistical significance to rapid progression of disease as estimated by log-rank-test. Conversely, low levels of sCD137L and high levels of sCD178 correlate significantly with prolongation of time to progression of disease. Our results indicate that serum levels of sCD137L and sCD178 represent valuable novel indicators for prognosis and disease progression and may be a useful parameter for treatment decisions in patients with MDS.
- Published
- 2004
12. Amifostine in Combination with Erythropoietin and G-CSF Promotes Multilineage Hematopoiesis in Patients with Myelodysplastic Syndrome
- Author
-
Werner Linkesch, Wilma Zinke, Siegfried Sormann, M. Eibl, Gerald Jaeger, and Peter Neumeister
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Disease course ,Amifostine ,In vivo ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Granulocyte Colony-Stimulating Factor ,Humans ,Medicine ,Cell Lineage ,In patient ,Erythropoietin ,Aged ,Aged, 80 and over ,Ineffective Hematopoiesis ,business.industry ,Hematology ,Middle Aged ,Blood Cell Count ,Hematopoiesis ,Clinical trial ,Haematopoiesis ,Treatment Outcome ,Myelodysplastic Syndromes ,Immunology ,business ,medicine.drug - Abstract
Ineffective hematopoiesis leading to profound cytopenias represents a major clinical problem in the management of patients with myelodysplastic syndrome (MDS). The aminothiol amifostine has shown to promote multilineage hematopoiesis both in vivo and in vitro in patients with MDS. We have treated 10 patients with 250 mg/m2 amifostine thrice weekly in combination with erythropoietin for 4 consecutive weeks followed by 2 weeks observation. Responding patients received the same 6 week schedule, while nonresponder received G-CSF in addition to erythropoietin and amifostine during the second treatment course. All patients experienced single or multilineage hematologic improvement, but only 2 reached transfusion independency. Moreover, response was durable only in a minority of patients and thus additional studies are warranted to further define the potential interaction of amifostine and growth factors.
- Published
- 2001
13. Serum erythropoietin at diagnosis in low grade myelodysplastic syndrome correlates with both red cell zinc protoporphyrin and serum lactic dehydrogenase (LDH) and may reflect severity of ineffective erythropoiesis
- Author
-
Suzanne McPherson, Karen Breen, Philip Murphy, and Jiri Slaby
- Subjects
Adult ,Male ,Ineffective erythropoiesis ,Cancer Research ,medicine.medical_specialty ,Serum erythropoietin ,Erythrocytes ,Anemia ,Protoporphyrins ,medicine.disease_cause ,Gastroenterology ,chemistry.chemical_compound ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Erythropoiesis ,Erythropoietin ,Aged ,Aged, 80 and over ,Ineffective Hematopoiesis ,L-Lactate Dehydrogenase ,Red Cell ,business.industry ,Myelodysplastic syndromes ,Zinc protoporphyrin ,Serum lactic dehydrogenase ,Hematology ,Middle Aged ,medicine.disease ,Oncology ,chemistry ,Myelodysplastic Syndromes ,Immunology ,Female ,business - Abstract
The myelodysplastic syndromes (MDS) are a heterogenous group of clonal hematological disorders, characterised by ineffective hematopoiesis [1]. Anemia in low grade MDS [refractory anemia (RA), refr...
- Published
- 2009
14. Proliferation and Differentiation of Myelodysplastic CD34+ Cells
- Author
-
Ken-ichi Sawada
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Neutropenia ,Acute myeloblastic leukemia ,CD34 ,Antigens, CD34 ,Biology ,Immunophenotyping ,Colony-Forming Units Assay ,Colony-Stimulating Factors ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Immunologic Factors ,Progenitor cell ,Cells, Cultured ,Ineffective Hematopoiesis ,Cytopenia ,Myelodysplastic syndromes ,Cell Differentiation ,Hematology ,Hematopoietic Stem Cells ,medicine.disease ,Haematopoiesis ,Leukemia, Myeloid ,Dysplasia ,Myelodysplastic Syndromes ,Immunology ,Disease Progression ,Cell Division - Abstract
Myelodysplastic syndromes (MDS) are a heterogeneous group of disorders of hematopoiesis involving hyperproliferative and ineffective hematopoiesis associated with morphologic evidence of marrow cell dysplasia resulting in refractory cytopenia(s), and an increased risk of transformation into acute myeloblastic leukemia (AML). The administration of colony-stimulating factor(s) (CSFs) to patients with MDS increased blood neutrophil concentrations, in most patients, and was also expected to be beneficial and to prevent infections. However, the progression to AML during the treatment with CSFs was suspected in some patients. Therefore, extensive in vitro studies were expected to lead to the establishment of criteria for selection of patients who are likely to benefit from CSF's as well as to establish the overall value of the different types of CSFs therapy. For this purpose, in vitro colony assays provide an excellent tool for investigating the biologic characteristics of MDS progenitor cells. However, conditions of the culture must be such that each progenitor can express its full potential for proliferation and differentiation. Because of the above, MDS progenitor cells cannot be used because they carry an impairment in proliferation and differentiation. To address this problem, one needs to know how many cells are being handled and the maximum numbers of colonies and clusters expected. CD34, a stem cell phenotype, is at present one of the best markers of progenitor cells, and can be used for purposes of purification. Using a defined number of CD34+ cells, it was feasible to make direct investigations on MDS progenitor cells. In this review the properties of MDS progenitor cells are described, in association with proliferation and differentiation, with special emphasis on the phenotypic subpopulations of MDS CD34+ cells.
- Published
- 1996
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.